Table 2

Proportion of patients taking ACEI/ARB who initiate AA in UK primary care 2004–2014 with blood tests at several time points post initiation of AA

7 days14 days1 month2 months3 months6 months1 year
1674/10 613
15.8%		3291/10 546
31.2%		5210/10 431
49.9%		6520/10 258
63.5%		7229/10 145
71.3%		8389/9962
84.2%		9294/9799
94.9%

  • The denominator changes due to patients exiting the cohort.

  • AA, aldosterone antagonist; ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker.